Novo Nordisk says trial data show an oral formulation of its GLP-1 analogue semaglutide provided superior HbA1c and weight reductions versus placebo in people with type II diabetes and renal impairment.
News
NHS managers warn no-deal Brexit risks drug shortages
NHS trusts are warning that the health service is not prepared for a no-deal Brexit and that drug supplies could be affected as a result.
US nod for Opdivo in pre-treated small cell lung cancer
US regulators have further expanded the scope of Bristol Myers Squibb’s Opdivo, approving its use for a previously treated small cell lung cancer.
Europe’s first allogeneic stem cell therapy rejected by NICE
Cost regulators for the NHS in England and Wales have not approved funding for TiGenix and Takeda’s Alofisel – the first allogeneic stem cell therapy to be approved for use across the European Union – for use in Crohn’s patients in draft guidelines.
Cases of type II diabetes surge in under-25s
The number of children and young people being treated for type II diabetes has leapt by around 40 percent in just four years to more than 700 cases, NHS data show.
Widespread confusion about cancer symptoms delaying diagnoses
Confusion about cancer symptoms among workers could be leading to delayed diagnoses and irregular self-examinations, suggests new research by Bupa UK.
Don’t miss the 7 September deadline
The PharmaTimes Sales Awards closes for entry in just a few weeks and with Sanofi, Allergan, LEO Pharma, Novartis and Bio Products Laboratory and many more besides signed up to take part, all signs are pointing to a very exciting debut indeed. It only takes a few seconds to fill out the online entry form and entrants need not do anything else until the day of the competition.
News of the inaugural Medical & Scientific Excellence Awards is spreading fast
With the importance of MSLs, scientific advisors and medical information professionals growing year on year – PharmaTimes Media has recognised this burgeoning area and gathered together an array of experts within the field to devise a challenging and rewarding competition that now includes seven categories.
NICE sticks with ‘no’ for use of Perjeta after breast cancer surgery
NICE is sticking with its position that Roche’s Perjeta is not cost-effective enough to be used by the NHS post surgery to prevent breast cancer recurrence.
Closing soon – ENTER NOW
The prestigious PharmaTimes Marketer of the Year competition closes for entries on 1 September. It only takes a few seconds to fill out the online entry form and then you don’t need to do anything else until the day of the competition. This year is extra special as the competition is celebrating its 25th anniversary – and we don’t want you to miss out.
Novo buys UK group Ziylo
Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out based at Unit DX science incubator in Bristol, UK.
Enter now for a place in history
It’s a double first for the Communications Team of the Year competition, as individuals within agencies and pharma companies battle it out for the ‘Aspiring Communications Manager of the Year’ title.
Teva, Regeneron’s fasinumab hits osteoarthritis goals
Teva and Regeneron Pharmaceuticals have unveiled positive topline results from a Phase III study assessing the safety and efficacy of fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or hip.
Lenvima wins green light in liver cancer
Eisai and MSD’s Lenvima (lenvatinib) has been approved in the US for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
PHE data shows link between cancer diagnosis route and treatment
Public Health England (PHE) has revealed new data showing that the way that cancer patients are diagnosed can affect their treatment options.
